PARIS, March 7 (Reuters) – If French food group Danone
decides to sell its slowing medical nutrition business, it is
most likely to invest the proceeds in its faster growth baby
food and dairy businesses, targeting acquisitions in Asia and
Reuters reported last month that the world’s No 1 yoghurt
maker was considering selling the unit which makes tube feeding
and other products, which has been under pressure from declining
healthcare budgets in Europe.
PARIS, March 5 (Reuters) – France’s Stallergenes
said on Wednesday it had appointed former Actelion
manager Christian Chavy as its new chief executive to drive the
company’s expansion into the U.S. immunotherapy market.
Stallergenes is hoping to win by the end of the month a U.S.
green light to launch its immunotherapy pill Oralair for the
treatment of grass allergies.
PARIS, March 4 (Reuters) – Caterer Elior said on Tuesday it
would return to French stock market by the summer after an
eight-year absence, in an estimated 4 billion euro ($5.51
billion) flotation that could be one of the largest on the Paris
bourse this year.
“Elior confirms (it is) preparing a stock market listing on
Euronext Paris by Summer 2014,” a company spokesman said.
PARIS (Reuters) – Carmat hopes to finish human trials of its artificial heart by the end of next year and to obtain regulatory approval for an EU launch by early 2015, its chief executive told Reuters.
The French company is also seeking a partner in the United States to enter the world’s largest healthcare market, and is in contact with Johnson & Johnson, Medtronic, St Jude Medical and Edwards Lifesciences, Marcello Conviti said.
PARIS, Oct 14 (Reuters) – Sanofi, trying to
squeeze more out of R&D spending like other big drugmakers, is
finding its home market France a difficult place to cut costs
because of complex labour laws, union opposition and a
government eager to protect jobs.
The company, which scaled back job cut plans in France a
year ago due to political pressure, will start a new round of
talks with unions on Tuesday that are likely to be tough.
PARIS (Reuters) – As French foods group Danone SA (DANO.PA: Quote, Profile, Research) grapples with a series of problems in China and other Asian markets, a sales update due in mid October will give the company the next chance to enlighten investors on the overall impact.
So far the maker of Aptamil, Actimel and Activia has played down the effects, even of an Asian recall of high-margin baby formula, but its sangfroid could yet be tested.
PARIS, Aug 27 (Reuters) – Accor has named private
equity specialist Sebastien Bazin as the French hotel group’s
new chairman and chief executive in a move expected to speed
Accor’s asset sales to boost investor returns.
The appointment of Bazin, who has ended all his duties as
head of European operations for U.S. investment fund Colony
Capital, Accor’s largest shareholder, was made at a board
meeting on Tuesday morning.
PARIS/TOULOUSE (Reuters) – Sanofi plans to cut 207 jobs in France as part of the drug company’s latest reshuffle of its research operations, which unions said would also lead to layoffs at vaccine and animal health divisions.
Sanofi management told union representatives on Tuesday that the group planned to cut 376 research jobs in France, offset by the creation of 169 new openings, mostly near Paris.
PARIS (Reuters) – French magistrates decided on Friday not to place IMF chief Christine Lagarde under formal investigation over her role in a 285-million-euro ($368.5 million) arbitration payment made to a supporter of former president Nicolas Sarkozy.
Lagarde instead was given the status of a “supervised witness” after two full days of questioning on her 2008 decision as Sarkozy’s finance minister to use arbitration to settle a legal battle between the state and businessman Bernard Tapie.
PARIS, May 14 (Reuters) – The French Competition Authority
fined drugmaker Sanofi 40.6 million euros ($52.7
million) on Tuesday for “disparaging” generic competition to its
Plavix blood thinner.
The decision on Tuesday follows a complaint filed in 2010 by
Teva Sante, a French unit of Israel-based Teva Pharmaceutical
Industries, against Sanofi’s communication practices
towards health professionals aimed at discouraging the use of
generic versions of Plavix.